SCHEMBL3625890

SCHEMBL3625890

CC(C)(C)OC(=O)C[S+]([O-])c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
CYP2C19 P33261 1/20 0.37
HIF1A Q16665 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
PTPRC P08575 2/20 0.35
ABCB1 P08183 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20892278 1.00 MTNR1A (0.37) MTNR1AMTNR1BCYP2C19HIF1ACA12
SCHEMBL22194965 0.85 MIF (0.37) MTNR1AMTNR1BCA12CA1CA7
SCHEMBL22195024 0.85 NR1D1 (0.36) MTNR1AMTNR1BALDH1A1MEN1KMT2A
SCHEMBL19403534 0.85 NR1D1 (0.36) MTNR1AMTNR1BALDH1A1MEN1KMT2A
SCHEMBL19385915 0.85 MIF (0.37) MTNR1AMTNR1BCA12CA1CA7
SCHEMBL22194738 0.84 NPC1 (0.38) MTNR1AMTNR1BCYP2C19CA1ALDH1A1
SCHEMBL6577170 0.84 GAA (0.38) CYP2C19MEN1KMT2ATSHRL3MBTL1
SCHEMBL19386050 0.84 GAA (0.38) CYP2C19MEN1KMT2ATSHRL3MBTL1
SCHEMBL22194737 0.84 NPC1 (0.38) MTNR1AMTNR1BCYP2C19CA1ALDH1A1
SCHEMBL22194886 0.84 NR1D1 (0.38) MTNR1AMTNR1BCYP2C19CA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646213-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE Arrowhead Pharmaceuticals, Inc. (US) 2025-11-12 EP disclosed
WO-2024148329-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE Arrowhead Pharmaceuticals, Inc. (US) 2024-07-11 WO disclosed
US-10710061-B2 Ion pair catalysis of tungstate and molybdate NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2020-07-14 US disclosed
EP-2217589-A2 MODULATORS OF OCULAR OXIDATIVE STRESS ReVision Therapeutics, Inc. (US) 2010-08-18 EP disclosed
US-20090253745-A1 MODULATORS OF OCULAR OXIDATIVE STRESS SIRION THERAPEUTICS, INC. (US) 2009-10-08 US disclosed
US-20090253745-A1 MODULATORS OF OCULAR OXIDATIVE STRESS SIRION THERAPEUTICS, INC. (US) 2009-10-08 US disclosed
WO-2009070693-A2 MODULATORS OF OCULAR OXIDATIVE STRESS SIRION THERAPEUTICS, INC (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253745-A1 MODULATORS OF OCULAR OXIDATIVE STRESS GPX4, GPX1, ALDH1A2 MTNR1A 106/4885MTNR1B 130/4885CYP2C19 2076/4885
US-10710061-B2 Ion pair catalysis of tungstate and molybdate PRDX3, PRDX4, PRDX2 MTNR1A 2697/4885MTNR1B 2600/4885CYP2C19 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.